Avatar wins hearts at Novartis mHealth challenge

Share this article:
Heart failure avatar wins hearts at Novartis mHealth challenge
Heart failure avatar wins hearts at Novartis mHealth challenge

While the majority of healthcare apps were recently found lacking—whether it be through their functionality or adoption (usually both)—a recent competition, conducted by Novartis, looked to buck that trend.

The drugmaker's two-day Mobile Health Challenge brought over 200 companies and developers to San Francisco to compete for cash prizes totaling $40,000. The aim was to develop “mobile platform-optimized and web-based solutions” that helped caregivers look after loved ones with heart failure.

The apps were rated on four criteria: how they addressed the challenges facing caregivers and patients, demonstration of a creative and innovative solution, ability to promote rapid uptake and use in the market, and  feasibility as a mobile solution.

Novartis chose to focus on heart failure due to the “the stress on caregivers and patients [which] can impact their emotional and physical health, and often goes unaddressed,” the company said in a statement, adding, “Innovative technology solutions is one of the many steps where we can help address this unmet need.”

Tina Tuttle, business partner, communications, for Novartis, told MM&M by e-mail: “The mHealth challenge reinforced the potential of mobile health applications and tools to facilitate caregiving outside of traditional healthcare settings; especially in the context of rising use of smartphones and other mobile technologies.”

“The core concept of the challenge was to capture the spirit of competition and to produce concepts outside the traditional design and development process,” Tuttle added.

The winning app—developed by Sense.ly—was a medical assistant avatar (pictured) that lets users remotely monitor a patient diagnosed with congestive heart failure (CHF). 

It scored high on three marks, said Tuttle. “The app has a simple user interface that leverages voice recognition, captures qualitative and quantities data, and provides information to assist with lifestyle decisions.”

Novartis said it intends to flesh out the prototype into a full-fledged app.

The app may come to fruition at the same time as Relaxin (serelaxin), a drug the company is currently investigating for the treatment of acute heart failure. Relaxin, which received FDA's Breakthrough Therapy Designation this past June, has been shown in trials to ease strain on blood vessels and the heart. Phase III results, released last November, demonstrated a 37% reduction in deaths compared to placebo.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.